Immunovant (IMVT) Grows 3.5% as Biotech Rally Spurs Investor Interest
Immunovant (IMVT) gains 3.51% as biotech rally continues, yet YTD decline & aggressive P/E raise caution; track 200‑day SMA & upcoming trial data.
2 minutes to read
IMMUNOVANT INC